Search results
Results from the WOW.Com Content Network
William Bradley Coley (January 12, 1862 – April 16, 1936) was an American bone surgeon and cancer researcher best known for his early contributions to the study of cancer immunotherapy, specifically causing infection as a way to fight cancer, a practice used as far back as 1550 BC. [1]
1900 – Swedish Dr. Stenbeck cures a skin cancer with small doses of radiation [4]; 1920s – Dr. William B. Coley's immunotherapy treatment, regressed tumors in hundreds of cases, the success of Coley's Toxins attracted heavy resistance from his rival and supervisor, Dr. James Ewing, who was an ardent supporter of radiation therapy for cancer.
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies .
The Breakthrough is written for the lay reader and includes sections on immunology that have been written for a general audience. It examines the development of cancer immunotherapy, starting with William Coley's work with toxins in the 1890s, moving on to the long hiatus of immunotherapy, and concluding with victory for the believers in the form of regulatory approval of CTLA-4, PD-1, and PD ...
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology ( immuno-oncology ) and a growing subspecialty of oncology .
Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for environmental allergies (such as insect bites) and asthma. [ 1 ] [ 2 ] Immunotherapy involves exposing people to larger and larger amounts of allergens in an attempt to change the immune system's response.
Azathioprine is used alone or in combination with other immunosuppressive therapy to prevent rejection following organ transplantation, and to treat an array of autoimmune diseases, including rheumatoid arthritis, pemphigus, systemic lupus erythematosus, Behçet's disease, and other forms of vasculitis, autoimmune hepatitis, atopic dermatitis, myasthenia gravis, neuromyelitis optica (Devic's ...
Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. [2] It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006.